Neurocrine Biosciences, Inc. (NBIX) on Decifer

Decifer ranks NBIX number 16 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 11% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 21% a year and profits grew 41% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It sits in a part of the market we are watching.
• And it returns cash to shareholders.
• As one of 5 credible suppliers of approved specialty-drug franchise ownership, revenue growing about 21% with profits up 41% and momentum of 25 out of 35 puts it inside a funded demand wave.

The current read

The evidence on NBIX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Neurocrine Biosciences, Inc. operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Read the full NBIX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.